4BB
NEUTRAL4basebio CEO Increases Stake
The CEO of the biotechnology company has purchased additional shares in the business on behalf of his children.
4basebio
1,122.50GBX
-0.22%
Market Cap
173.67M
Volume
337
34% of avg
P/E Ratio
-0.19
EPS (TTM)
-60
Beta
1.06
Day Range
1,100.00p - 1,122.50p
52 Week Range
1,090.00p1,122.50p1,820.00p
1,122.50p
Upcoming Events
1 July 2025
Next allocation of shares under the employee incentive plan
4BB
GOOD4basebio Receives GMP Licence for UK Manufacturing Facility
The biotechnology company has received a key regulatory certification for its UK manufacturing facility, strengthening its position in advanced therapeutics.
4BB
NEUTRAL4basebio PLC Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
4BB
NEUTRAL4basebio PLC announces RBC Capital Markets initiates research coverage
The biotechnology company announces that RBC Capital Markets has initiated research coverage.
4BB
NEUTRAL4basebio PLC Announces Employee Share Incentive Plan
The biotechnology company has announced an employee share incentive plan, issuing new shares to be held in trust for eligible employees.
4BB
NEUTRAL4basebio COO Increases Shareholding
The biotechnology company's COO has acquired additional shares, increasing her stake in the business.
4BB
GOOD4basebio Appoints New Chief Commercial Officer to Drive Growth
Biotechnology company 4basebio appoints new Chief Commercial Officer to drive growth in synthetic DNA solutions.
4BB
GOOD4basebio Appoints Industry Veteran Alan Malus to Board
Biotechnology company 4basebio strengthens its leadership with the appointment of an industry veteran to its board.
4BB
NEUTRAL4basebio CEO Acquires Additional Shares
Positive news as 4basebio's CEO buys more shares, but the impact is likely limited due to the small size of the transaction.
4BB
NEUTRAL4basebio CEO Transfers Shares Between Accounts
Biotech company 4basebio announces routine share transfer by CEO